Anavex Life Sciences Corp. reported a peer-reviewed publication in the journal Neuroscience Letters, titled “Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer’s disease model.” This study demonstrated that pre-treatment with blarcamesine entirely prevented Amyloid beta-induced memory impairment and brain oxidative injury in an animal model.
These findings suggest that blarcamesine is an attractive candidate for Alzheimer's disease pharmacological prevention. The author of the publication, Tangui Maurice, PhD, Research Director at University of Montpellier, France, highlighted that this preclinical study clearly demonstrates a preventative effect of blarcamesine in Alzheimer’s pathology.
The mechanistic confirmation that blarcamesine restores impaired autophagy through SIGMAR1 activation, acting upstream of amyloid and tau pathologies at the molecular level, was also emphasized. This mechanism, combined with convenient once-daily oral administration, supports the future direction of clinical trials to explore blarcamesine’s potential as a safe and effective pharmacologic agent for Alzheimer's disease prevention.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.